Trials establish efficacy of tretinoin lotion in acne
A new study published in the Journal of Drugs in Dermatology reports that Tretinoin 0.05% lotion provides statistically significant efficacy with a highly favourable safety and tolerability profile in moderate-to-severe acne patients.
Stephen K. Tyring and colleagues conducted a study to evaluate the efficacy, safety, and tolerability of a novel tretinoin 0.05% lotion in moderate-to-severe acne in patients aged 9 years and older.
Read Also:An effective, Safe Combo Therapy for Severe Inflammatory Acne
A total of 1640 patients aged 9-58 years of age were included in the study. The study participants were randomized to receive either tretinoin 0.05 percent lotion or vehicle. two double-blind, placebo-controlled 12-week, 2-arm, parallel group studies.
Key study findings included :
- Tretinoin 0.05% lotion demonstrated statistically significant superiority to the vehicle in reducing inflammatory and noninflammatory lesion counts at week 12 and improving acne severity.
- At week 12, mean percent change in inflammatory and noninflammatory lesions were 52% and 46%, respectively.
- Treatment success (a 2-grade improvement in EGSS and ‘clear’ or ‘almost clear’ was reported in 18% of patients.
- Tretinoin 0.05% lotion also showed significantly greater benefits relative to vehicle control in terms of patient satisfaction and acne-specific QoL domains.
- Tretinoin 0.05% lotion was very well tolerated with no substantive differences in cutaneous tolerability among treatment groups.
- No patients discontinued treatment because of adverse events.
Read Also:Sarecycline is the new drug approved for Acne by FDA
According to Bill Humphries, president of Ortho Dermatologics, these new data further demonstrate the value that ALTRENO Lotion provides patients with acne vulgaris, and they look forward to bringing the product to market by the end of the month.
Acne vulgaris is a chronic inflammatory disease of the skin that affects the individuals of all ages, especially adolescents and young adults. Globally, it affects 85% of individuals aged 12 to 25 years.